ישראל -
עברית -
Ministry of Health
טרוקוקסיל 95 מג טבליות לעיסות לכלבים וטרינרי
zoetis israel holding b.v., israel - mavacoxib - טבליות לעיסות - mavacoxib 95 mg - for the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated
ישראל -
עברית -
Ministry of Health
טרוקוקסיל 75 מג טבליות לעיסות לכלבים וטרינרי
zoetis israel holding b.v., israel - mavacoxib - טבליות לעיסות - mavacoxib 75 mg - for the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated
ישראל -
עברית -
Ministry of Health
טרוקוקסיל 30 מג טבליות לעיסות לכלבים וטרינרי
zoetis israel holding b.v., israel - mavacoxib - טבליות לעיסות - mavacoxib 30 mg - for the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated
ישראל -
עברית -
Ministry of Health
טרוקוקסיל 20 מג טבליות לעיסות לכלבים וטרינרי
zoetis israel holding b.v., israel - mavacoxib - טבליות לעיסות - mavacoxib 20 mg - for the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated
ישראל -
עברית -
Ministry of Health
אלימטה 500 מג
eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
ישראל -
עברית -
Ministry of Health
אלימטה 500 מג
eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
ישראל -
עברית -
Ministry of Health
אלימטה
eli lilly israel ltd, israel - pemetrexed - אבקה להכנת תמיסה לאינפוזיה - pemetrexed 100 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.